Compare NICE & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NICE | ICUI |
|---|---|---|
| Founded | 1986 | 1984 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.6B |
| IPO Year | 1999 | 1995 |
| Metric | NICE | ICUI |
|---|---|---|
| Price | $104.68 | $152.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | $153.46 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 345.7K | 184.9K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 1.96 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $10.14 | N/A |
| Revenue Next Year | $9.62 | $4.46 |
| P/E Ratio | ★ $11.21 | $78.02 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $83.10 | $112.50 |
| 52 Week High | $153.07 | $192.85 |
| Indicator | NICE | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 26.54 |
| Support Level | $96.03 | $146.59 |
| Resistance Level | $104.84 | $160.22 |
| Average True Range (ATR) | 3.52 | 4.61 |
| MACD | -0.08 | -2.03 |
| Stochastic Oscillator | 52.22 | 5.18 |
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.